Interaction analysis of high-risk pathological features on adjuvant chemotherapy survival benefit in stage II colon cancer patients: a multi-center, retrospective study

被引:0
|
作者
Li, Kexuan [1 ]
Zhao, Fuqiang [2 ]
Guo, Yuchen [3 ]
Wu, Qingbin [4 ]
Luo, Shuangling [5 ,6 ,7 ]
Zhang, Junling [8 ]
Li, Heli [9 ]
Hu, Shidong [10 ]
Wu, Bin [1 ]
Lin, Guole [1 ]
Qiu, Huizhong [1 ]
Niu, Beizhan [1 ]
Sun, Xiyu [1 ]
Xu, Lai [1 ]
Lu, Junyang [1 ]
Du, Xiaohui [10 ]
Wang, Zheng [9 ]
Wang, Xin [8 ]
Kang, Liang [5 ,6 ,7 ]
Wang, Ziqiang [4 ]
Wang, Quan [3 ]
Liu, Qian [2 ]
Xiao, Yi [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gen Surg, Div Colorectal Surg, 1 Shuai Fu Yuan Rd, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp,Dept Diagnost Radiol, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China
[3] First Hosp Jilin Univ, Gen Surg Ctr, Dept Gastrointestinal Surg, 1 Xin Min Ave, Changchun 130021, Peoples R China
[4] Sichuan Univ, West China Hosp, Colorectal Canc Ctr, Dept Gen Surg, 37 Guo Xue Xiang, Chengdu 610041, Peoples R China
[5] Sun Yat sen Univ, Affiliated Hosp 6, Dept Gen Surg Colorectal Surg, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[6] Sun Yat sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Dis, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[7] Sun Yat sen Univ, Affiliated Hosp 6, Biomed Innovat Ctr, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[8] Peking Univ First Hosp, Dept Gastrointestinal Surg, 8 Xi Shi Ku St, Beijing 100034, Peoples R China
[9] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, 1277 Jiefang Ave, Wuhan 430022, Peoples R China
[10] Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 1, Dept Gen Surg, 28 Fu Xing Rd, Beijing 100853, Peoples R China
基金
中国国家自然科学基金;
关键词
Colon cancer; High-risk pathological features; Adjuvant chemotherapy; PERINEURAL INVASION; PREDICTIVE FACTOR; PROGNOSTIC-FACTOR; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; OUTCOMES; THERAPY; TRIAL;
D O I
10.1186/s12885-023-11196-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We aimed to analyze the benefit of adjuvant chemotherapy in high-risk stage II colon cancer patients and the impact of high-risk factors on the prognostic effect of adjuvant chemotherapy. Methods This study is a multi-center, retrospective study, A total of 931 patients with stage II colon cancer who underwent curative surgery in 8 tertiary hospitals in China between 2016 and 2017 were enrolled in the study. Cox proportional hazard model was used to assess the risk factors of disease-free survival (DFS) and overall survival (OS) and to test the multiplicative interaction of pathological factors and adjuvant chemotherapy (ACT). The additive interaction was presented using the relative excess risk due to interaction (RERI). The Subpopulation Treatment Effect Pattern Plot (STEPP) was utilized to assess the interaction of continuous variables on the ACT effect. Results A total of 931 stage II colon cancer patients were enrolled in this study, the median age was 63 years old (interquartile range: 54-72 years) and 565 (60.7%) patients were male. Younger patients (median age, 58 years vs 65 years; P < 0.001) and patients with the following high-risk features, such as T4 tumors (30.8% vs 7.8%; P < 0.001), grade 3 lesions (36.0% vs 22.7%; P < 0.001), lymphovascular invasion (22.1% vs 6.8%; P < 0.001) and perineural invasion (19.4% vs 13.6%; P = 0.031) were more likely to receive ACT. Patients with perineural invasion showed a worse OS and marginally worse DFS (hazardous ratio [HR] 2.166, 95% confidence interval [CI] 1.282-3.660, P = 0.004; HR 1.583, 95% CI 0.985-2.545, P = 0.058, respectively). Computing the interaction on a multiplicative and additive scale revealed that there was a significant interaction between PNI and ACT in terms of DFS (HR for multiplicative interaction 0.196, p = 0.038; RERI, -1.996; 95%CI, -3.600 to -0.392) and OS (HR for multiplicative interaction 0.112, p = 0.042; RERI, -2.842; 95%CI, -4.959 to -0.725). Conclusions Perineural invasion had prognostic value, and it could also influence the effect of ACT after curative surgery. However, other high-risk features showed no implication of efficacy for ACT in our study.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Clinical Practice in the Use of Adjuvant Chemotherapy for Patients with Colon Cancer in South Korea: a Multi-Center, Prospective, Observational Study
    Kim, Jung Han
    Baek, Moo Jun
    Ahn, Byung-Kwon
    Kim, Dae Dong
    Kim, Ik Yong
    Kim, Jin Soo
    Bae, Byung-Noe
    Seo, Bong-Gun
    Jung, Sang Hun
    Hong, Kwan Hee
    Kim, Hungdai
    Park, Dong Guk
    Lee, Ji Hye
    JOURNAL OF CANCER, 2016, 7 (02): : 136 - 143
  • [22] Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study
    Alwers, Elizabeth
    Jansen, Lina
    Blaeker, Hendrik
    Kloor, Matthias
    Tagscherer, Katrin E.
    Roth, Wilfried
    Boakye, Daniel
    Herpel, Esther
    Gruellich, Carsten
    Chang-Claude, Jenny
    Brenner, Hermann
    Hoffmeister, Michael
    MOLECULAR ONCOLOGY, 2020, 14 (02) : 363 - 372
  • [23] Development of a Risk Score and Nomogram to Predict Individual Benefit Attained from the Addition of Adjuvant Chemotherapy in the Treatment of Stage II Colon Cancer
    Nelson, Daniel W.
    Merritt, Clay
    Chang, Shu-Ching
    Grunkemeier, Gary
    Steele, Scott R.
    Goldfarb, Melanie
    JOURNAL OF GASTROINTESTINAL SURGERY, 2021, 25 (01) : 220 - 232
  • [24] Survival of Adjuvant Chemotherapy Among Elderly Patients with Stage II Colon Cancer
    Tsai, Tsung-Chih
    Sun, Jia-Ling
    Lin, Wen-Li
    Lee, Sung-Wei
    Chang, Shu-Chan
    Wu, Pei-Hua
    Huang, Wen-Tsung
    Tsao, Chao-Jung
    INTERNATIONAL JOURNAL OF GERONTOLOGY, 2018, 12 (02) : 94 - 99
  • [25] Patient Selection for Adjuvant Chemotherapy in High-Risk Stage II Colon Cancer A Systematic Review and Meta-Analysis
    Zhang, Chao
    Yin, Songcheng
    Tan, Yuen
    Huang, Jinyu
    Wang, Pengliang
    Hou, Wenbin
    Zhang, Zhe
    Xu, Huimian
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (04): : 279 - 287
  • [26] Stratified Survival Analysis After Adjuvant Chemotherapy of Colon Cancer Reveals a Benefit for Older Patients
    Mayer, Benjamin
    Sander, Silvia
    Paschke, Stephan
    Henne-Bruns, Doris
    Link, Karl-Heinrich
    Kornmann, Marko
    ANTICANCER RESEARCH, 2015, 35 (10) : 5587 - 5593
  • [27] Receipt of Adjuvant Chemotherapy in Stage II Colon Cancer and Overall Survival: A National Cancer Database Study
    Enofe, Nosayaba
    Morris, Andrew D.
    Liu, Yuan
    Liang, Wendi
    Wu, Christina S.
    Sullivan, Patrick S.
    Balch, Glen G.
    Staley, Charles A.
    Gillespie, Theresa W.
    Shaffer, Virginia O.
    JOURNAL OF SURGICAL RESEARCH, 2020, 252 : 69 - 79
  • [28] Clinical implication of adjuvant chemotherapy according to mismatch repair status in patients with intermediate-risk stage II colon cancer: a retrospective study
    Kang, Byung Woog
    Baek, Dong Won
    Chang, Eunhye
    Kim, Hye Jin
    Park, Su Yeon
    Park, Jun Seok
    Choi, Gyu Seog
    Baek, Jin Ho
    Kim, Jong Gwang
    JOURNAL OF YEUNGNAM MEDICAL SCIENCE, 2022, 39 (02): : 141 - 149
  • [29] Safety and Survival Benefit of Adjuvant Chemotherapy for Elderly Patients With Stage II/III Colon Cancer
    Yang, In Jun
    HA Kim, Dong
    Lee, Kyung-ha
    Kim, Ji yeon
    ANTICANCER RESEARCH, 2025, 45 (02) : 797 - 809
  • [30] Retrospective analysis of a Bi-National Colorectal Cancer Audit to characterize stage II colon cancer patients who were offered adjuvant chemotherapy
    Cooper, Edward A.
    Buxey, Kenneth N.
    Maslen, Ben J.
    Muhlmann, Mark
    ANZ JOURNAL OF SURGERY, 2020, 90 (06) : 1136 - 1140